Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.7
USERS' SCORE
Moderately Good
Based on 14 Reviews
7.9
Supplement Facts
Serving Size: 2 Capsules
Amount Per Serving
%DV
Total Carbohydrate
<1 g
<1%†
Calcium (from calcium magnesium phytate)
131 mg
10%
Phosphorus (from calcium magnesium phytate)
192 mg
15%
Magnesium (from calcium magnesium phytate)
40 mg
10%
IP-6 (inositol hexaphosphate) (from calcium magnesium phytate)
800 mg
**
Inositol
220 mg
**
Top Medical Research Studies
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
9
We explored the effects of intrathecal pemetrexed (IP) on lung cancer patients facing leptomeningeal metastases (LM), particularly after they had not responded to previous treatments with EGFR-TKIs. The study analyzed 50 patients who received a 50 mg dose of IP after their cancer progressed, looking closely at their clinical responses and survival outcomes over two years.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Read More
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
Read More
Most Useful Reviews
9
Cancer-free status
22 people found this helpful
This product was recommended to my husband and is excellent for strengthening the cells that fight disease. We use it to support his lung cancer battle, and after a year of treatment, he is now cancer-free. We believe this product has played a role in his recovery and tumour shrinkage.
Read More
9
Preventive effects
2 people found this helpful
I have used this for many years; it claims to keep cancer cells at bay, and so far, so good.
Read More
9
Helped recovery
2 people found this helpful
This product worked wonders, really aiding my mum's recovery from lung cancer. I also mixed it with black seed oil and highly recommend it.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.7
- All Researches
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
9
We explored the effects of intrathecal pemetrexed (IP) on lung cancer patients facing leptomeningeal metastases (LM), particularly after they had not responded to previous treatments with EGFR-TKIs. The study analyzed 50 patients who received a 50 mg dose of IP after their cancer progressed, looking closely at their clinical responses and survival outcomes over two years.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Remarkably, we observed a 64% clinical response rate, indicating that many patients saw improvements in their neurological symptoms and overall performance. The median intracranial progression-free survival was 5.3 months, while overall survival reached up to 12 months for these patients. Those who responded positively to the treatment experienced significantly longer survival compared to non-responders, which is encouraging for both patients and doctors seeking options after traditional therapies fail.
The treatment was generally well tolerated, with manageable side effects mostly related to myelosuppression and liver functions. Additionally, genetic testing revealed consistency between the tumors and the cerebrospinal fluid, which opens up further investigation into the underlying mechanisms of treatment resistance. Overall, our findings suggest that IP could be a promising option for patients battling advanced lung cancer with LM after existing therapies have stopped working.
Read More
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 14 Reviews
7.9
- All Reviews
- Positive Reviews
- Negative Reviews
9
Cancer-free status
22 people found this helpful
This product was recommended to my husband and is excellent for strengthening the cells that fight disease. We use it to support his lung cancer battle, and after a year of treatment, he is now cancer-free. We believe this product has played a role in his recovery and tumour shrinkage.
Read More
9
Preventive effects
2 people found this helpful
I have used this for many years; it claims to keep cancer cells at bay, and so far, so good.
Read More
9
Helped recovery
2 people found this helpful
This product worked wonders, really aiding my mum's recovery from lung cancer. I also mixed it with black seed oil and highly recommend it.
Read More
9
Reduced skin cancers
1 people found this helpful
Since taking this product, my skin cancers have reduced. I take two capsules daily.
Read More
9
Effective for patients
1 people found this helpful
This is a highly effective antioxidant for lung cancer patients, and all who take this supplement notice significant improvements.
Read More
Frequently Asked Questions
7.5
Effective treatment
1 people found this helpful
As a lung cancer patient, I experienced a drop in my cancer index after taking two bottles. However, I also use many other health products, so this is part of my overall strategy.
7.5
Pain relief
1 people found this helpful
IP6 has reduced but mainly alleviated the pain from inflammation in my lungs. I take it twice daily on an empty stomach, and I hope to see improvements in my phosphorus level at my next check-up.
7.5
Incredible results
2 people found this helpful
IP6 is a phenomenal supplement for many health issues. I used it for my parent with lung cancer, and the results were remarkable. I recommend it for others with similar conditions, as research supports its effectiveness.
9
Helped recovery
2 people found this helpful
This product worked wonders, really aiding my mum's recovery from lung cancer. I also mixed it with black seed oil and highly recommend it.
9
Reduced skin cancers
1 people found this helpful
Since taking this product, my skin cancers have reduced. I take two capsules daily.
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
References
- Cui Z, Mu C, Wu Z, Pan S, Cheng Z, et al. The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth. Cell Death Dis. 2022;13:569. doi:10.1038/s41419-022-05017-y
- Kassie F, Bagherpoor AJ, Kovacs K, Seelig D. Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: association with immunomodulation. Carcinogenesis. 2022;43:547. doi:10.1093/carcin/bgac019
- Li L, Huang Z, Chen Y, Ma H, Chen X, et al. Intrathecal pemetrexed improves survival outcomes in previously treated EGFR-mutant advanced non-small-cell lung cancer with leptomeningeal metastases. Heliyon. 2024;10:e40703. doi:10.1016/j.heliyon.2024.e40703
